| MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. | leukemia, |
| Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. | leukemia, |
| Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene. | leukemia, |
| Patients with t(12;22)/MN1-EVT6 oncogene, are frequently associated with myeloid neoplasms, poor response to chemotherapy, and inferior outcome. | neoplasm, |
| The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. | None |
| Targeted disruption of the Mn1 oncogene results in severe defects in development of membranous bones of the cranial skeleton. | None |
| MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. | None |
| The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence. | None |
| MN1 is a unique oncogene in hematopoiesis that both promotes proliferation/self-renewal and blocks differentiation, and may become useful as a predictive marker in AML treatment. | None |